Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
An **epitope** (also called an antigenic determinant) is the specific part of an antigen that is recognized by the immune system, either through binding by antibodies (such as IgG) or recognition by T cell receptors on T cells[1][7]. B cell epitopes are recognized by antibodies or B cell receptors and are typically conformational (dependent on 3D structure) or linear segments of proteins. T cell epitopes are presented on the surface of antigen-presenting cells bound to major histocompatibility complex (MHC) molecules, chiefly as short peptides (8–11 amino acids for MHC I, 13–17 for MHC II)[1][5]. Some epitopes in IgG, known as **Tregitopes**, have regulatory properties, activating natural T regulatory cells and promoting immune tolerance[2][3][4]. Epitopes can be exploited in immunotherapy, vaccine design, allergy treatment, and in understanding immune responses in various diseases. However, "IgG/T-cell epitopes" is not a standardized or canonical target name and should not be treated as a single molecular entity but rather as a functional immune feature shared by many antigens[1][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Epitope.